Biotech Values

[mcbio]

Polymedix:

I've spent the last 2 weeks reading papers from the company in regards to their antibiotic platform and the work appears solid to me (given my limitations in this field). The publications are even in relatively decent journals.

Anyone know of any red flags?

Phase 2 data is due this quarter on the antibiotic and this is really the first actual efficacy study of the drug in infected patients so this is a big event to watch for the company to see if they can show PoC. Most of the comments have been cautiously optimistic on the drug but the first real sign of proof will come with this data.

I had some general questions about the MoA of the drug under item 2 of #msg-48713859 and David Miller got a response direct from the company that he posted in #msg-48778970. I also posted some questions/potential concerns regarding safety (liver elevations/tingling) in item 1 of that post that David also responded to in #msg-48774984. Not sure if you have any comments on side effects.

What are your thoughts on the other half of the PYMX story, the potential replacement for Protamine that they are developing?

All told, seems like an interesting company and valuation doesn't exactly look expensive. I have them at least on my watch list but I need to see a little more before I would consider them.